UMCG to study potential coronavirus vaccine: volunteers sought
The UMCG is going to study a potential COVID-19 vaccine:
the AKS-452 vaccine produced by Akston Biosciences in the United States.
The goal of the study is to research the safety and tolerability of and the reaction of the immune system to the vaccine. For the study, the UMCG is looking for 176 healthy volunteers aged between 18 and 65 who are willing to be vaccinated with the potential vaccine.
How does the vaccine work?
The Akston Biosciences vaccine is a ‘recombinant subunit vaccine’. In this type of vaccine, the actual coronavirus (weakened or alive) is not used. The vaccine is made from a particle of the virus, the spike protein, which is fused with a protein fragment from a human antibody. The vaccine is contained in a liquid or adjuvant that strengthens the immune response.
The human body recognizes that the spike protein belongs to the coronavirus and initiates a defence mechanism, through which antibodies and T cells are produced. Through this technique, a natural reaction against viral infection is imitated and the body’s immune system is activated. The advantage of this type of vaccine is that it does not contain any genetic material of the virus and it is therefore impossible for the virus to multiply in the body.
The vaccine has already been extensively tested in animal models for COVID-19 infections, in which it appears to be effective and safe. The next phase is to research the safety and tolerability of and the reaction of the immune system to the vaccine in humans.
Volunteers sought
The UMCG is looking for 176 healthy volunteers, aged above 18 and below 65, who have not yet been infected with SARS-CoV-2 or received another potential or established coronavirus vaccine. The research participants will receive either one or two doses of the potential vaccine to establish the dosage needed to achieve a sufficient number of antibodies. Participants will still be able to receive another coronavirus vaccine at a later stage.
About Akston Biosciences
Akston Biosciences is located in Beverly, Massachusetts and is specialized in the development of new fusion proteins to develop and produce new biological treatments for the prevention of type 1 diabetes, for long-acting insulin treatment and for vaccines. The AKS-452 vaccine is based on this technique, which uses the conventional production techniques of antibodies. More information can be found at www.akstonbio.com .
Last modified: | 22 February 2022 2.17 p.m. |
More news
-
15 May 2024
Part of the children with ADHD can stop using Ritalin sooner
A part of children with ADHD could stop taking Ritalin after two years. This is the conclusion of Anne-Flore Matthijssen's PhD research.
-
06 May 2024
Impact: 'URinControl', treatment of urine loss through app
One of the three researchers nominated for the Ben Feringa Impact Award 2024 is general practicioner and researcher-epidemiologist Anne Loohuis. Loohuis conducted research on the treatment of urine loss through the self-help app URinControl'.
-
29 April 2024
Royal Decoration awarded to Gerard van den Berg
The Faculty of Economics and Business is very proud to announce that Professor Gerard van den Berg has been appointed Officer of the Order of Orange-Nassau. The decoration was presented to him by Mayor Koen Schuiling of the Municipality of...